A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.

Inclusion Criteria

• •Among hemodialysis patients with secondary hyperparathyroidism due to chronic kidney disease (CKD 5D), those who are scheduled to administer Pacitol Inj. according to the product information.
• •Those who voluntarily signed a written personal information collection and usage agreement to participate in this clinical study after receiving an explanation about the objective and methods of the study.
• •Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.